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Background: To explore the activity of dasatinib alone and in combination with gemcitabine and docetaxel in
uterine leiomyosarcoma (uLMS) cell lines, and determine if dasatinib inhibits the SRC pathway.
Methods: SK-UT-1 and SK-UT-1B uLMS cells were treated with gemcitabine, docetaxel and dasatinib individually
and in combination. SRC and paxcillin protein expression were determined pre- and post-dasatinib treatment using
Meso Scale Discovery (MSD) multi-array immunogenicity assay. Dose-response curves were constructed and the
coefficient of drug interaction (CDI) and combination index (CI) for drug interaction calculated.
Results: Activated phosphorylated levels of SRC and paxillin were decreased after treatment with dasatinib in both
cell lines (p < 0.001). The addition of a minimally active concentration of dasatinib (IC25) decreased the IC50 of
each cytotoxic agent by 2-4 fold. The combination of gemcitabine-docetaxel yielded a synergistic effect in SK-UT-1
(CI = 0.59) and an antagonistic effect in SK-UT-1B (CI = 1.36). Dasatinib combined with gemcitabine or docetaxel
revealed a synergistic anti-tumor effect (CDI < 1) in both cell lines. The triple drug combination and sequencing
revealed conflicting results with a synergistic effect in SK-UT-1B and antagonistic in SK-UT-1.
Conclusion: Dasatinib inhibits the SRC pathway and yields a synergistic effect with the two-drug combination with
either gemcitabine or docetaxel. The value of adding dasatinib to gemcitabine and docetaxel in a triple drug
combination is uncertain, but may be beneficial in select uLMS cell lines. Based on our pre-clinical data and known
activity of gemcitabine and docetaxel, further evaluation of dasatinib in combination with these agents for the
treatment of uLMS is warranted.
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Leiomyosarcomas (LMS) are a rare and aggressive type of
uterine malignancy that has an extremely poor prognosis.
Uterine sarcomas represent only 3-9% of all uterine
malignancies and LMS account for 40% of all uterine
sarcomas [1,2]. Even in the setting of early-stage disease
53 to 71% of women will develop recurrences that are
often extra-pelvic and incurable. The prognosis is dismal
with a historical progression-free survival rate at 2 years* Correspondence: micael.lopez@duke.edu
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article, unless otherwise stated.(PFS2 yrs) of only 30% for patients treated with surgery
alone [3].
Chemotherapy with a combination of gemcitabine and
docetaxel has shown the most promise to date. The
overall response rate has ranged from 42% to 53% with a
median duration of response of greater than 7 months in
women with unresectable LMS [4]. Most recently,
adjuvant gemcitabine and docetaxel was evaluated in
women with completely resected stage I to IV uterine
LMS. The PFS2 yrs was 45% with a median PFS of
13 months and the median survival was not yet reached
[3]. Despite these modest improvements, there is an urgent
need for innovative therapeutic approaches.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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nib (BMS-354825) (NSC 732517). Dasatinib is a potent,
orally-bioavailable, small molecule inhibitor that has been
shown to inhibit at least five protein tyrosine kinases/kinase
families: SRC family kinases, BCR-ABL, c-KIT, EPHA2 and
the PDGFβ receptor [5,6]. SRC kinase interacts with a
variety of receptor tyrosine kinases such as EGFR, PDGFR,
and c-KIT as well as other cellular factors such as focal
adhesion kinase (FAK). These pathways are integral
components of cellular function and regulate cellular
migration, proliferation, survival, angiogenesis, and metas-
tasis. The SRC pathway and its substrates (FAK) as well as
c-KIT, EGFR and PDGF tyrosine kinase receptors
have been found to be overexpressed in a wide variety of
sarcomas including LMS [7-9]. Most recently, Shank et al.
showed that EGFR, VEGF and c-KIT is expressed in
uterine LMS specimens [9]. In particular, 57% of uterine
LMS specimens express c-KIT.
Given the activity of gemcitabine and docetaxel as well as
the pre-clinical data regarding the SRC pathway in LMS,
we sought to explore the activity of dasatinib (a SRC inhibi-
tor) in combination with these cytotoxic agents in uLMS.
Methods
Drugs
Gemcitabine and docetaxel were purchased from Sigma
(St. Louis, MO). Dasatinib (BMS-354825) was provided
by Bristol-Myers-Squibb (Princeton, NJ) via the National
Cancer Institute (NCI). Dasatinib, gemcitabine and
docetaxel were dissolved in dimethylsulfoxide (DMSO).
Concentrated stock solutions of all drugs were stored
at -25°C.
Cell culture
SK-UT-1 and SK-UT-1B cell lines were obtained from
the American Type Culture Collection (Manassas, VA).
SK-UT-1 and SK-UT-1B cell lines are uterine in origin.
Cell lines were grown and maintained in monolayer
culture in RPMI 1640 (Gibco) media supplemented
with 10% fetal bovine serum (Hyclone, Logan UT),
1% sodium pyruvate, 100 units/ml penicillin, 100 ug/ml
stremptomycin and 1% nonessential amino acids in a
humidified chamber containing 5% CO2.
Meso scale discovery (MSD) analysis
MSD analysis was performed for SRC and paxillin. Paxillin
is a SRC pathway substrate that is phosphorylated by
SRC and FAK upon integrin binding or growth factor
stimulation. Cells were seeded at 3×106 cells per plate
of each cell line, and allowed to reach confluence over
24 hours. Cells were incubated at 37°C for 24 hours with
dasatinib at a escalating concentrations of 30, 100 and
500 nmol/L. Controls were treated with DMSO. Anti-total
Src antibody (tSrc) (Cell Signaling Technology, Inc.,Danvers, MA, Cat#2108), anti-pSrc pY418 antibody
(Invitrogen, Carlsbad, CA, Cat# 44660G), anti-total
paxillin antibody (Cell Signaling Technology, Inc., Danvers,
MA, Cat#2542), or anti-phospho paxillin (Tyr118) antibody
(Cell Signaling Technology, Inc., Danvers, MA, Cat#2541)
were added at 1ug/ml to bare, goat anti-mouse plates (MSD,
Gaithersburg MD), and incubated at room temperature
(R.T.) for 1 hour. The plates were washed with TBS/ 0.05%
Tween-20 three times and protein lysate from SK-UT-1
(20 ug total protein) or SK-UT-1B (20 ug total protein)
cells were added and incubated for 2 hours at R.T.
Sulfo-TAG (MSD, Cat#R91AN-1) labeled anti-Src anti-
body (R&D, Cat# AF3389) were then added to the plates
and incubated for 1 hour at room temperature after plates
were washed. The plates were imaged and analyzed using
a MSD Sector Imager 2400 and associated software. The
electroluminescence value was normalized to each control
and plotted as a percent of control. Statistical analysis was
performed using two-tailed unpaired t-test.
Cell proliferation assay
Tumor cells were seeded at a density of 2,500 cells/well in a
96-well plate, and allowed to reach 70% confluence over
24 hours. Cells were then incubated with each drug at 37°C
for 72 hours with escalating doses: docetaxel (0.1 nmol/
L-1000 nmol/L), gemcitabine (0.1 nmol/L-100 nmol/L) and
dasatinib (10 nmol-4000 nmol/L). Control wells contained
RPMI media only. All experiments were done using
exponentially proliferating cells. After the 72 hours
drug incubation period, 5 μl of ATP luminescence solution
was added to each well and cell proliferation was measured
by ATP content using the Luminescence ATP cell detection
assay system according to manufacturer’s recommenda-
tions. Experiments to determine the IC50 were performed
in triplicate.
The percentage of growth inhibition was calculated using
the following: survival ratio = # live cellstreated group /#live
cellscontrol group × 100. The half maximal inhibitory concen-
tration (IC50) was defined as the drug concentration at
which the 50% of the cell growth was inhibited and was
analyzed using GraphPad Prism software (version 4.03
San Diego, CA). Single-agent dose response curves were
constructed and the IC50 for gemcitabine and docetaxel
was computed from the best fitting transition functions
(determined by F-statistic). The average IC50 of all
experiments performed was chosen as the final IC50.
Given the lack of significant activity of dasatinib as a
single-agent, the IC25 was calculated from the dose
response curve. The cells were subsequently treated
with combinations of gemcitabine and docetaxel; dasatinib
and gemcitabine; dasatinib and docetaxel; and the
three-drug simultaneous and sequential combination
of gemcitabine, docetaxel, and dasatinib. For gemcitabine
and docetaxel, fixed-ratio molar concentrations ranging
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Dasatinib was added at a fixed 1:1 ratio using the IC25.
Two-drug combination effect evaluation and statistical
methodologies
The IC50 obtained for single-agent gemcitabine and
docetaxel was compared to the IC50 calculated for each
cytotoxic agent after adding dasatinib IC25. To analyze
the drug interaction between both cytotoxic agents and
dasatinib combined with either agent, the coefficient of
drug interaction (CDI) was calculated. CDI is defined by
the following formula; CDI = AB/(A × B) [10,11].
According to the absorbance of the luminescence of
each group, AB is the ratio of the two-drug combination
group to the control group, and A or B is the ratio of the
single drug group to the control group. CDI < 1 indicates
synergism, CDI < 0.7 significant synergism, CDI = 1
additivity and CD > 1 antagonism [11]. Due to the lack of
significant activity of dasatinib and the inability to obtain
an IC50 for this agent, the CDI formula was utilized to
evaluate the anti-proliferative effect between dasatinib and
each cytotoxic agent. This formula permits calculation of
drug-to-drug interaction without a requisite IC50. All
experiments were performed in duplicate.
Triple drug simultaneous and sequential combination
effect evaluation and statistical methodologies
To evaluate the growth inhibition effect of dasatinib
with gemcitabine and docetaxel in a triple-drug combin-
ation, we used the median effect method, which takes
into account the potency of each drug combination and
the shape of the dose-response curve [12,13]. Composite
dose response curves were obtained from three independent
experiments and the median effective dose, Dm (equivalent
to the IC50) was computed using CalcuSyn software
(Biosoft, Cambridge, UK). Drug interaction was assessed
by the combination index (CI) method of Chou and
Talalay [12,13]:
CI ¼ Dð ÞA = Dxð ÞA þ Dð ÞB = Dxð ÞB
þ α Dð ÞA Dð ÞB = Dxð ÞA Dxð ÞB
where D is the dose that yields x% growth inhibition and
α = 0 for mutually exclusive drugs (the drugs have
similar sites of action). Combination index scale was
defined as: CI <0.9 synergistic, CI = 0.9-1.1 additive,
CI = 1.1-1.2 slight antagonism, CI = 1.2-1.45 moderate
antagonism, CI = 1.45-3.3 antagonism, CI = 3.3-10 strong
antagonism.
In contrast to the two-drug combination where the
CDI formula was used, the median effect (CI formula)
method was utilized to evaluate triple-drug interaction.
This was possible because both gemcitabine and docetaxel
reached an IC50 as single agents. For sequencing studies,drug exposures were separated by 24 hours. The combin-
ation index between gemcitabine and docetaxel was
computed with and without the addition of dasatinib
IC25. All experiments were performed in triplicate.
Results
Meso scale discovery (MSD) analysis
SRC protein expression
The level of SRC activation (pSRC) was determined using
MSD analysis. In SK-UT-1, treatment with dasatinib
resulted in a loss of SRC activation (pSRC/tSRC) at 30 nm
(16%; p < 0.001), 100 nm (8%; p < 0.001) and 500 nm (2%;
p < 0.001) (Figure 1). The pSRC signal from SK-UT-1 was
at least 15-fold higher than the pSRC signal from the con-
trol cells (Additional file 1: Figure S1). In SK-UT-1, there
was an increase in tSRC after treatment with single-
agent dasatinib at 30 nm (148%, p < 0.001), 100 nm
(181%, p < 0001) and 500 nm (172%, p < 0.001) compared
to controls (Additional file 2: Figure S2). In contrast, pSRC
levels were significantly decreased after treatment with
dasatinib at 30 nm (24%, p < 0.001), 100 nm (14%, p < 0.001)
and 500 nm (3%, p < 0.001) (Additional file 3: Figure S3).
In SK-UT-1B, there was a loss of SRC activation at
30 nm (11%, p < 0.001), 100 nm (11%, p < 0.001) and
500 nm (5%, p < 0.001) compared to controls (Figure 1).
There was a decrease in pSRC levels after treatment with
single-agent dasatinib at 30 nm (17%, p < 0.001), 100 nm
(7%, p < 0.001) and 500 nm (4%, p < 0.001) and an increase
in tSRC after treatment with single-agent dasatinib at
30 nm (152%, p < 0.001), but a decrease at 100 nm (64%,
p < 0.001) and 500 nm (74%, p < 0.001) (Additional file 2:
Figure S2 and Additional file 3: Figure S3).
Paxillin protein expression
In SK-UT-1, the ratio of p-paxillin/t-paxillin was unchanged
after treatment with dasatinib at 30 nm (90%, p < 0.001)
and 100 nm (110%, p < 0.001), but there was a significant
reduction at 500 nm (16%, p < 0.001) (Figure 2). There was
a significant loss of t-paxillin expression after treatment
with dasatinib at 500 nm (73%, p = 0.01), but no change at
30 nm (113%, p = 0.06) and 100 nm (92%, p = 0.2)
compared to controls (data not shown). Similar results
were observed for p-paxillin levels, with a significant loss
after treatment with dasatinib at 500 nm (11%, p < 0.001),
but no change at 30 nm (100%) or 100 nm (100%) (data
not shown).
In SK-UT-1B, activation of paxillin (p-paxillin/t-paxillin)
was significantly inhibited by the presence of dasatinib
at 30 nm (76%), 100 nm (1%) and 500 nm (3%) (Figure 2).
There was an increase in t-paxillin expression after treat-
ment with dasatinib at 100 nm (198%, p < 0.001), but no
change at 30 nm (76%, p = 0.02) or 500 nm (93%, p = 0.2)
(data not shown). The expression of p-paxillin was reduced
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Figure 1 The pSRC/tSRC ratio after treatment with single-agent dasatinib. In SK-UT-1, activation of the SRC kinase (pSRC/tSRC) pathway was
inhibited by dasatinib at 30 nm (84%), 100 nm (92%) and 500 nm (98%). In SK-UT-1B, the SRC kinase activity was reduced in the presence of
dasatinib at 30 nm (91%), 100 nm (91%) and 500 nm (95%).
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shown).
Anti-proliferative activity of single-agent gemcitabine,
docetaxel and dasatinib
The IC50 for gemcitabine and docetaxel as single agents
was calculated for each cell line (Table 1). Growth inhib-





































   
   











Figure 2 The p-paxillin/t-paxillin ratio after treatment with single-age
by the presence of dasatinib at 500 nm in SK-UT-1 (16%); and 30 nm (14%)SK-UT-1 (21.7% inhibition) and for SK-UT-1B (32.8%).
Using increasing concentrations of dasatinib, the maximal
growth inhibitory effect of dasatinib for SK-UT-1 was
42.8% (1000 nm) and 55.5% (4000 nm) for SK-UT-1B
(Figure 3). The dasatinib IC50 for SK-UT-1B was
381 nmol/L. Higher concentrations did not achieve
greater growth inhibition. In the SK-UT-1 cell line an
IC50 was not reached. The IC25 (25% growth inhibition)Control
SK-UT-1B
30 nM 100 nM 500 nM
eatment
* *
nt dasatinib. Activation of paxillin (p-paxillin/t-paxillin) was inhibited
, 100 nm (1%) and 500 nm (3%) in SK-UT-1B.
Table 1 IC50 of each cytotoxic agent alone and in
combination with dasatinib (IC25) and coefficient of drug
interaction (CDI)
Cell Line Drugs IC50 CDI
SK-UT-1
Gemcitabine 4.02 (SD ± 1.0)
Docetaxel 4.30 (SD ± 0.5)
Gemcitabine:Dasatinib IC25 2.35 (SD ± 1.4) 0.72
Docetaxel:Dasatinib IC25 1.15 (SD ± 0.07) 0.80
SK-UT-1B
Gemcitabine 2.97 (SD ± 0.5)
Docetaxel 0.94 (SD ± 0.6)
Gemcitabine:Dasatinib IC25 0.85 (SD ± 0.6) 0.83
Docetaxel:Dasatinib IC25 0.52 (SD ± 0.4) 0.93
SD = standard deviation.
IC50 = 50% of maximal inhibitory concentration.
IC25 = 25% of maximal inhibitory concentration.
CDI = Coefficient of drug interaction. Calculation utilize when one drug does
not achieve an IC50.
CDI scale = CDI < 1 indicates synergism between dasatinib and cytotoxic
agents, whereas CDI < 0.7 indicates significant synergism.
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each cell line. The IC25 for dasatinib was 100 nm for both
cell lines.
Drug interaction assessment for combination dasatinib
and cytotoxic chemotherapy
The IC25 of dasatinib calculated for each cell line was
used in combination with different concentrations of
gemcitabine (e.g. 10, 7.5, 5, 2.5, 1 nm) and docetaxel
(e.g. 40, 20, 10, 5, 1 nm) mixed at a fixed ratio (1:1),
respectively. The IC50 obtained from the single agent
response curves for both gemcitabine and docetaxel was
then compared to the IC50 calculated after adding dasatinib





















Figure 3 Growth inhibition assay. Dasatinib showed minimal to modest
effect for SK-UT-1 and SK-UT-1B was 42.8% and 55% respectively.dasatinib reduced the IC50 of both gemcitabine and
docetaxel for each cell line ranging from 2:1 to 4:1
(2-4 fold inhibition) (Table 1) (Figure 4).
For SK-UT-1 and SK-UT-1B, the combination of
gemcitabine-dasatinib at all concentrations analyzed
demonstrated decreased cell viability (Figure 5A and E)
and yielded a CDI <1 indicating synergistic effects
(average CDI = 0.72 and 0.83 for SK-UT-1 and SK-UT-1B,
respectively) (Figure 5B and F). Similarly, in both cell
lines the combination of docetaxel-dasatinib demonstrated
decreased cell viability (Figure 5C and G) and synergistic
effects (average CDI = 0.80 and 0.93 for SK-UT-1 and
SK-UT-1B, respectively) (Figure 5D and H).
The median effect analysis for combining gemcitabine
and docetaxel revealed synergistic effect in SK-UT-1
(CI = 0.59) and moderate antagonism in SK-UT-1B
(CI = 1.36) (Table 2). The results of the simultaneous
and sequential drug experiments using dasatinib IC25,
gemcitabine and docetaxel in a triple-drug combination
are shown in Table 2. The greatest anti-proliferative
activity (synergistic) in SK-UT-1 was seen with the
simultaneous triple-drug combination of dasatinib,
gemcitabine and docetaxel (CI = 0.46). The remainder
of the sequential triple-drug combinations revealed a
moderate antagonistic effect (CI = 1.07-1.8) (Table 2).
In SK-UT-1B, the simultaneous triple-drug combination
of gemcitabine, docetaxel and dasatinib revealed moderate
antagonistic effect (anti-proliferative effect (CI = 1.4)).
Sequential dasatinib followed by combination gemcitabine
and docetaxel as well as gemcitabine followed by combin-
ation docetaxel and dasatinib yielded synergistic effects
(CI = 0.9 for both). In contrast, combination dasatinib and
docetaxel followed by gemcitabine demonstrated an
additive effect (CI = 1.0). The remaining sequential combi-
nations produced an antagonistic effect (CI ranging
from 1.21-1.5) (Table 2).10 100 250 500 1000 2000 4000
tinib [nM]
SK-UT-1B
activity against leiomyosarcoma cell lines. Maximal growth inhibitory
A. B. 
C.                                                                          D.
Figure 4 IC50 obtained from single agent response curves for gemcitabine and docetaxel was compared to the IC50 obtained after
adding dasatinib at a minimally active concentration (IC25). Graphics above represents the results of a single experiment for SK-UT-1
(A & B) and SK-UT-1B (C & D). (Gem = gemcitabine; Das = dasatinib; Doc = docetaxel).
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Dasatinib has not been shown to be a potent agent when
used alone in a variety of solid tumors [14]. Schrage et al.
previously reported their findings of dasatinib in
chondrosarcoma cell lines [15]. The maximum percent of
growth inhibition in the chondrosarcoma cell lines was
approximately 50%. They also explored dasatinib’s
effect on SRC phosphorylation and caspase-3- mediated
apoptosis. Although dasatinib treatment of chondrosarcoma
decreased SRC phosphorylation, indicating target inhibition,
it did not result in an increase in apoptosis. Therefore, the
inhibition of SRC and its family of kinases was not sufficient
to promote cell death. In a large clinical trial of patients
with incurable sarcoma, which included 47 participants
with LMS, dasatinib did not have a significant anti-tumor
activity as a single agent [16]. Based on pre-clinical and
clinical data, it appears that single agent dasatinib does not
have significant clinical activity in soft tissue sarcomas.
However, our pre-clinical study investigating the activity
of dasatinib in combination with gemcitabine and docetaxel
in uterine LMS demonstrates that dasatinib acts synergis-
tically with gemcitabine or docetaxel in a two-drug combin-
ation and in select triplet combinations in the analyzed
uterine LMS cell lines. Our findings in sequential and triple
combination yielded conflicting results. Interestingly, the
simultaneous triple-drug combination of dasatinib IC25,
gemcitabine and docetaxel in SK-UT-1 yielded a synergisticeffect, although the magnitude of that effect is probably
minimal (CI = 0.59 to 0.46). Conversely, the gemcitabine
and docetaxel doublet demonstrated an antagonistic effect
in SK-UT-1B cells and that effect was not reversed with the
addition of dasabinib in the simultaneous triple-drug
combination. However, in select sequencing experiments,
dasatinib enhanced the anti-proliferative effect of gemcita-
bine and docetaxel; gemcitabine + docetaxel + dasatinib;
dasatinib followed by docetaxel + gemcitabine; and
gemcitabine followed by docetaxel + dasatinib. In the
latter two experiments, this finding may be due to avoid-
ance of the antagonistic interaction of the gemcitabine
and docetaxel doublet in the SK-UT-1B cell line as well as
partially attributed to the synergistic effect of the dasatinib
doublet. The results with the sequential dasatinib followed
by combination gemcitabine and docetaxel indicate a
possible role for priming with dasatinib.
We hypothesize that our synergistic findings may in
part be due to the inhibition of the SRC pathway. Our
MSD analysis revealed that dasatinib inhibited the
SRC pathway based on reduction of pSRC and p-paxillin
protein expression and ratios pSRC/tSRC and p-paxcillin/
t-paxillin. Even at very low doses of dasatinib (30 nM), the
SRC pathway was inhibited in both uLMS cell lines. This
suggests that an optimal biologic effect on SRC can occur
with low doses of dasatinib. However, expression of








































































































































































Figure 5 The inhibitory effect of gemcitabine and docetaxel at different concentrations combined with dasatinib IC25 and the
coefficient of drug interaction (CDI). CDI < 1 indicates synergism, CDI < 0.7 significant synergism, CDI = 1 additivity and CD > 1 antagonism. In
SK-UT-1, the combination of gemcitabine-dasatinib, at all concentrations analyzed demonstrated decreased cell viability (A) and yielded a CDI <1
indicating synergistic effects (average CDI = 0.72) (B); the combination of docetaxel-dasatinib demonstrated decreased cell viability (C) and synergistic
effects (average CDI = 0.80) (D). In SK-UT-1B the combination of gemcitabine-dasatinib, at all concentrations analyzed demonstrated decreased cell
viability (E) and yielded a CDI <1 indicating synergistic effects (average CDI = 0.83) (F); the combination of docetaxel-dasatinib demonstrated
decreased cell viability (G) and synergistic effects (CDI = 0.93) (H).
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Table 2 The combination index (CI) in uterine LMS cell
lines
Cell Line Drugs Combination index
(CI) at the IC50
SK-UT-1
Gemcitabine:Docetaxel 0.59
Gemcitabine + Docetaxel + Dasatinib 0.46
Dasatinib- > Gemcitabine + Docetaxel 1.77
Gemcitabine + Docetaxel- > Dasatinib 1.14
Dasatinib + Gemcitabine- > Docetaxel 1.32
Dasatinib + Docetaxel- > Gemcitabine 1.07
Gemcitabine- > Docetaxel + Dasatinib 1.8
Docetaxel- > Gemcitabine + Dasatinib N/D
SK-UT-1B
Gemcitabine:Docetaxel 1.36
Gemcitabine + Docetaxel + Dasatinib 1.4
Dasatinib- > Gemcitabine + Docetaxel 0.9
Gemcitabine + Docetaxel- > Dasatinib 1.36
Dasatinib + Gemcitabine- > Docetaxel 1.21
Dasatinib + Docetaxel- > Gemcitabine 1.0
Gemcitabine- > Docetaxel + Dasatinib 0.9
Docetaxel- > Gemcitabine + Dasatinib 1.5
Combination index scale: CI <0.9 synergistic, CI = 0.9-1.1 additive, CI = 1.1-1.2
slight antagonism,
CI = 1.2-1.45 moderate antagonism, CI = 1.45-3.3 antagonism, CI = 3.3-10
strong antagonism.
N/D = not determined.
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SRC pathway may be activated via different pathways.
The SRC pathway is a complex pathway with convergent
and divergent interactions. It is not clear that the
anti-proliferative effect we noted in our study was a
direct result of inhibition of the SRC pathway. Most
recently, Shank et al. showed that EGFR, VEGF and
especially c-KIT were expressed in uterine LMS specimens
[9]. In particular, 57% of uterine LMS specimens expressed
c-KIT. Therefore, dasatinib’s anti-proliferative effect
seen in our study may be via the inhibition of the c-KIT
pathway in addition to or instead of inhibition of the
SRC pathway.
Another important property of dasatinib not related to
cytotoxicity, lies in its ability to inhibit migration and
cell invasion. Dasatinib has been shown to inhibit cell
migration in non-small cell lung cancer, head and neck
squamous cell cancer, neuroblastoma, and multiple soft
tissue and bone sarcoma cell lines [8,17,18]. Johnson and
colleagues reported that the anti-migratory effects of
dasatinib were present regardless of the effects seen on
proliferation and survival [17]. In addition, Shor et al.
showed that dasatinib significantly inhibited cellular
invasion using matrigel invasion chambers. With theexception of one rhabdomyosarcoma cell line, the IC50
dose to inhibit cell migration and invasion in the soft tissue
sarcoma cell lines ranged from 4-65 nmol/L and was
similar to the IC50 dose (range 3 nmol/L to 68 nmol/L) to
inhibit SRC phosphorylation [8]. This finding suggests that
SRC inhibition may be responsible for suppression of
sarcoma cellular migration and invasion. The universal
effects seen on migration and invasion suggest that benefi-
cial clinical effects may be achieved without direct cancer
cell cytotoxicity and provides a possible role of dasatinib in
preventing metastasis. Inhibition of metastasis is especially
important in aggressive tumors such as LMS which are
known to rapidly spread to distant sites.
While we and others have reported synergistic and
additive effects with dasatinib and a variety of chemo-
therapeutic agents in preclinical studies of ovarian and
breast cancer cell lines and ovarian cancer xenografts
[19-21], the clinical activity of dasatinib either alone or
in combination with cytotoxic agents in solid tumors
has been disappointing. In a phase I trial of dasatinib in
combination with paclitaxel and carboplatin in patients
with advanced or recurrent ovarian cancer, the triplet
combination demonstrated clinical activity but was also
associated with a higher than expected rate of hematologic
toxicity. Pharmacokinetic analysis showed that concurrent
administration of dasatinib with paclitaxel did not signifi-
cantly alter either dasatinib or paclitaxel drug concentra-
tions [14]. Two randomized studies of another SRC
inhibitor, saracatinib, with chemotherapy in ovarian cancer
demonstrated no improvement in response rate or survival,
but higher toxicity [22,23]. Therefore, the addition of
dasatinib to chemotherapy is unlikely to be beneficial
in an unselected patient population and there is a
need to identify biomarkers that can be used to direct
therapy. Of note, these studies used the maximum
tolerated dose (MTD). In our data, we observed an
increased antiproliferative effect of dasatinib in combin-
ation with cytotoxic agents at a minimal active dose. Hence,
combination effects may be beneficial at lower doses of
dasatinib in the treatment of uterine leiomyosarcoma.
Up-regulation of the SRC pathway has been shown to
be associated with resistance to cytotoxic therapy. In
mucinous ovarian cancer cell lines, Matsuo et al.
revealed that treatment with oxaliplatin induced phos-
phorylation of SRC kinase and this contributed to the
chemoresistance observed in this tumor. This induced
activity was subsequently inhibited by concurrent admin-
istration of dasatinib, which resulted in a synergistic
anti-tumor effect [24].
To our knowledge, there are no clinical trials that have
evaluated the toxicity of gemcitabine and docetaxel in com-
bination with dasatinib. In a prospective trial of women with
completely resected uterine leiomyosarcoma, treatment with
gemcitabine plus docetaxel was generally well-tolerated.
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docetaxel in the advanced disease setting included pulmon-
ary toxicity and myelosuppression requiring administration
of granulocyte-colony stimulating factor [3]. Based on our
prior experience, we anticipate that the addition of dasatinib
to gemcitabine and docetaxel would be associated with even
greater hematologic toxicity. A phase I evaluation would be
required to determine if biologically relevant doses could be
delivered with the triplet combination. However, the dispar-
ate sequential combination results in our cell lines was not
expected and requires further study. Alternatively, doublet
therapy with dasatinib plus gemcitabine or docetaxel
may be more effective than triplet therapy.
We acknowledge the limitations of our study, which
include the use of only two LMS cell lines rather than
primary tumor, and the use of in vitro models. Further
investigation in in vivo models is warranted to confirm our
in vitro results. Further study is also needed to determine if
dasatinib exerts its function via inhibition of the SRC
pathway or via other tyrosine kinases, such as BCR-ABL,
c-KIT, EPHA2, EGFR and PDGF, or a combination. In
summary, we are the first to report an anti-proliferative
effect of dasatinib in combination with cytotoxic agents in
uterine leiomyosarcoma.
Additional files
Additional file 1: Figure S1. Expression of phospho SRC (pSRC) in the
SK-UT-1 cell line. “KDR” are vascular endothelial growth factor cells use as
control group. Compare to this group, both SKUT-1 and SKUT-1B
demonstrated a much higher pSRC signal.
Additional file 2: Figure S2. The total SRC protein expression after
treatment with single agent dasatinib in SK-UT-1 and SK-UT-1B cell
lines. In SK-UT-1, there was an increase in tSRC after treatment with
single-agent dasatinib at 30 nm (148%, p<0.001), 100 nm (181%, p<0001)
and 500 nm (172%, p<0.001) compared to controls. In SK-UT-1B, there
was an increase in tSRC after treatment with single-agent dasatinib at 30
nm (152%, p<0.001), but a decrease at 100 nm (64%, p<0.001) and 500
nm (74%, p<0.001).
Additional file 3: Figure S3. pSRC protein expression after treatment
with single agent dasatinib in SK-UT-1 and SK-UT-1B cell lines. In
SK-UT-1, pSRC levels were significantly decreased after treatment with
dasatinib at 30 nm (24%, p<0.001), 100 nm (14%, p<0.001) and 500 nm
(3%, p<0.001). In SK-UT-1B, there was a decrease in pSRC levels after
treatment with single-agent dasatinib at 30 nm (17%, p<0.001), 100 nm
(7%, p<0.001) and 500 nm (4%, p<0.001).
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